Dr. Bauml on Next Steps for Immunotherapy in Head and Neck Cancer

Joshua Bauml, MD
Published: Tuesday, Jul 25, 2017



Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.

The next steps for immunotherapy in this disease is moving it earlier in the course of treatment, says Bauml.

For example, neoadjuvant pembrolizumab (Keytruda) showed major pathologic responses after a single dose in patients with resectable tumors.
 
SELECTED
LANGUAGE


Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.

The next steps for immunotherapy in this disease is moving it earlier in the course of treatment, says Bauml.

For example, neoadjuvant pembrolizumab (Keytruda) showed major pathologic responses after a single dose in patients with resectable tumors.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x